Yahoo
NYSE USD

Waters Corporation (WAT)

462.72 -17.35 (-3.61%)
At close: October 30 at 4:02:39 PM EDT
462.72 0.00 (0.00%)
After hours: October 30 at 4:08:35 PM EDT
Trade Waters on Coinbase
Chart Range Bar
Loading chart for WAT

What's happening with WAT?

36m ago
Powered by Yahoo Scout

Waters is approaching its November 3 third-quarter reportwith expectations for strong revenue and earnings growth, supported by acquisitions and pharmaceutical testing demand. Recent product launches expand Waters’ software strategy, while valuation concerns and China-related weakness remain key counterpoints.

Powered by Yahoo Scout
  • Previous Close 480.07
  • Open 479.04
  • Bid 461.61 x 4000
  • Ask 461.85 x 16000
  • Day's Range 458.85 - 479.60
  • 52 Week Range 282.77 - 482.28
  • Volume 1,342,305
  • Avg. Volume 811,933
  • Market Cap (intraday) 45.433B
  • Beta (5Y Monthly) 1.15
  • PE Ratio (TTM) 121.45
  • EPS (TTM) 3.81
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 465.86
  • Morningstar Rating Rating available with Stock Picks access

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

www.waters.com

16,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WAT
21.82%
S&P 500 (^GSPC)
10.73%

1-Year Return

WAT
34.94%
S&P 500 (^GSPC)
11.11%

3-Year Return

WAT
95.49%
S&P 500 (^GSPC)
81.91%

5-Year Return

WAT
25.89%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.27B
Earnings -72M
Profit Margin -5.68%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
500M
1B
0.0%
10.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

349.00 Low
465.86 Average
462.72 Current
530.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 475 -> 515

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.59%

  • Return on Assets (ttm)

    3.56%

  • Return on Equity (ttm)

    1.92%

  • Revenue (ttm)

    4.64B

  • Net Income Avi to Common (ttm)

    166.63M

  • Diluted EPS (ttm)

    3.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    539M

  • Total Debt/Equity (mrq)

    36.04%

  • Levered Free Cash Flow (ttm)

    -142.07M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: